[A18-60] Trametinib (melanoma) - Benefit assessment according to §35a Social Code Book V
Last updated 22.03.2019
Project no.:
A18-60
Commission:
Commission awarded on 24.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection
Advantage in overall survival and recurrence, disadvantages in side effects; indication of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| G19-06 | Trametinib (melanoma) - Addendum to Commission A18-60 | Commission completed |
| G24-08 | Trametinib (malignant glioma with BRAF V600E mutation in children aged 1 year and older) – Assessment according to §35a SGB V (1), Sentence 11 | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.